Any observed reductions in alcohol consumption while taking GLP-1 medications should be discussed with healthcare providers, and comprehensive addiction treatment should remain the standard of care
Please consult a medical professional before adopting any of the suggestions on this page
This type of product may be less aligned with your needs if you require clinically validated weight management outcomes comparable to prescription medications, prefer full-disclosure CFU counts per individual strain, or expect rapid changes within the first week of use
The GIP activation may provide some protective effect against GLP-1-related nausea, a pattern also observed with Tirzepatide
Pharmacological treatment of hyperglycemia in type 2 diabetes
For chronic weight management, the FDA-approved indications generally include adults with a BMI of 30 or greater, or BMI 27 or greater with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)